Risk factors and diagnostic biomarkers for asymptomatic immune checkpoint inhibitor-related myocarditis in patients with esophageal cancer after immunotherapy

Table 1 Baseline characteristics of participants, mean ± SD/n (%)

Parameters	Non-occurrence group (n = 134)	Occurrence group (n = 68)	t/χ2 value	P value
Age (years)	62.36 ± 7.34	65.49 ± 8.96	2.654	0.009
Gender (male/female)	56 (41.79)/78 (58.21)	42 (61.76)/26 (38.24)	7.205	0.007
Body mass index (kg/m²)	21.36 ± 3.25	20.56 ± 3.44	1.622	0.106
Education level			0.782	0.676
Primary and below	24 (17.91)	9 (13.24)
Middle school	45 (33.58)	23 (33.82)
College and above	65 (48.51)	36 (52.94)
Marital status			0.640	0.726
Married	119 (88.81)	60 (88.24)
Divorced	11 (8.21)	7 (10.29)
Unmarried	4 (2.99)	1 (1.47)
Segmentation of lesions			3.179	0.365
Neck	42 (31.34)	16 (23.53)
Upper thoracic segment	35 (26.12)	25 (36.76)
Mid thoracic segment	36 (26.87)	19 (27.94)
Lower thoracic segment	21 (15.67)	8 (11.76)
Length of lesion			0.509	0.476
> 5 cm	78 (58.21)	36 (52.94)
≤ 5 cm	56 (41.79)	32 (47.06)
Tumor staging system staging			0.552	0.907
Phase I	12 (8.96)	6 (8.82)
Phase II	35 (26.12)	21 (30.88)
Phase III	41 (30.6)	20 (29.41)
Phase IV	46 (34.33)	21 (30.88)
Organizational classification			0.031	0.861
Squamous cell carcinoma	109 (81.34)	56 (82.35)
Adenocarcinoma	25 (18.66)	12 (17.65)
Hypertension	16 (11.94)	4 (5.88)	1.856	0.173
Diabetes	11 (8.21)	3 (4.41)	0.506	0.477
Coronary heart disease	14 (10.45)	4 (5.88)	1.158	0.282
ICI			5.195	0.023
ICI combination therapy	43 (32.09)	33 (48.53)
ICI monotherapy	91 (67.91)	35 (51.47)
Chemotherapy	52 (38.81)	26 (38.24)	0.006	0.937

ICI: Immune checkpoint inhibitor.